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Sphingosine 1-phosphate lyase deficiency
causes Charcot-Marie-Tooth neuropathy
ABSTRACT
Objective: To identify the unknown genetic cause in a nuclear family with an axonal form of periph-
eral neuropathy and atypical disease course.
Methods: Detailed neurologic, electrophysiologic, and neuropathologic examinations of the
patients were performed. Whole exome sequencing of both affected individuals was done. The
effect of the identified sequence variations was investigated at cDNA and protein level in
patient-derived lymphoblasts. The plasma sphingoid base profile was analyzed. Functional conse-
quences of neuron-specific downregulation of the gene were studied in Drosophila.
Results: Both patients present an atypical form of axonal peripheral neuropathy, characterized by
acute or subacute onset and episodes of recurrent mononeuropathy. We identified compound
heterozygous mutations cosegregating with disease and absent in controls in the SGPL1 gene,
encoding sphingosine 1-phosphate lyase (SPL). The p.Ser361* mutation triggers nonsense-
mediated mRNA decay. The missense p.Ile184Thr mutation causes partial protein degradation.
The plasma levels of sphingosine 1-phosphate and sphingosine/sphinganine ratio were increased
in the patients. Neuron-specific downregulation of the Drosophila orthologue impaired the
morphology of the neuromuscular junction and caused progressive degeneration of the chemo-
sensory neurons innervating the wing margin bristles.
Conclusions:We suggest SPL deficiency as a cause of a distinct form of Charcot-Marie-Tooth dis-
ease in humans, thus extending the currently recognized clinical and genetic spectrum of in-
herited peripheral neuropathies. Our data emphasize the importance of sphingolipid
metabolism for neuronal function. Neurology® 2017;88:533–542
GLOSSARY
AR 5 autosomal recessive; CHX 5 cycloheximide; CMT 5 Charcot-Marie-Tooth disease; DQ 5 dosage quotient; HNA 5
hereditary neuralgic amyotrophy; HNPP 5 hereditary neuropathies with liability to pressure palsies; LL 5 lower limb;MRC 5
Medical Research Council; NCS5 nerve conduction studies;NCV5 nerve conduction velocities; NMD5 nonsense-mediated
mRNA decay; NMJ 5 neuromuscular junction; PF 5 plantar flexion; SMA 5 spinal muscular atrophy; SO/SA 5 sphingosine/
sphinganine; SPL 5 sphingosine 1-phosphate lyase; UL 5 upper limb; WES 5 whole exome sequencing.
Charcot-Marie-Tooth disease (CMT) represents a heterogeneous group of peripheral neuropa-
thies affecting 1:2,500 individuals.1 CMT is characterized by progressive length-dependent
degeneration of peripheral motor and sensory neurons, resulting in distal muscles weakness
and wasting, motor impairment, sensory loss, and skeletal deformities. The disease is classified
into CMT1, with median motor nerve conduction velocities (NCVs) ,38 m/s and histologic
evidence of demyelination and remyelination; CMT2, with normal or slightly reduced NCVs
and axonal changes; and intermediate CMT, with NCVs ranging between 25 and 45 m/s and
histopathologic signs of both demyelination and axonal degeneration.2,3
CMT shows all modes of inheritance, with autosomal recessive forms (AR-CMT) accounting
for ,10% of the European CMT population.4 This is likely underestimated due to the usually
small sibship size, with many AR-CMT cases being considered sporadic. There are .24
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AR-CMT genes explaining the disease in
a small subset of patients.5 Most AR-CMT
families carry private mutations in rare causal
genes, challenging their molecular diagnosis.
Furthermore, the encoded proteins are
involved in diverse cellular processes and the
cause-effect relationship is unclear. The exten-
sive etiologic heterogeneity impedes the devel-
opment of effective treatment strategies.
Here, we report a candidate gene (SGPL1)
for AR-CMT2 with atypical disease course.
Studies in patient-derived biosamples suggested
that this phenotype is due to partial loss of
SGPL1 function. Neuron-specific downregula-
tion of the Drosophila orthologue impaired the
morphology of the neuromuscular junction
(NMJ) and caused progressive neurodegenera-
tion, emphasizing the role of SGPL1 in estab-
lishing neuronal contact sites and axonal
maintenance.
METHODS Standard protocol approvals and patient
consents. Written informed consent was obtained. This study
was approved by the local institutional review boards.
Clinical and electrophysiologic evaluations. Patients and
parents underwent routine neurologic examinations. Motor
examination followed Medical Research Council (MRC) scale.
Standard nerve conduction studies (NCS) with surface electrode
and concentric needle EMGwere performed using a Premier elec-
tromyograph (Medelec, Woking, UK).6
Morphologic studies. Nerve biopsy was obtained from left su-
ral nerve and was examined as described.7
Whole exome sequencing (WES) and homozygosity
mapping. WES was performed at Beijing Genomics Institute,
China. Exomes were captured with SureSelect Human All Exon
V5 array (Agilent, Santa Clara, CA) followed by paired‐end
sequencing on Hiseq2000 (Illumina, San Diego, CA). Sequenc-
ing read mapping, variant calling, and annotation were done
using GenomeComb.8 Homozygosity mapping was performed
as described.9
Mutation analysis. SGPL1 (NM_003901.3, NP_003892.2)
was analyzed by Sanger sequencing as described.9 Pathogenicity
was predicted with Condel (bg.upf.edu/fannsdb/) and MetaSnp
(snps.biofold.org/meta-snp/).
Cohort screening. The cohort contained 107 AR-CMT cases
and 803 sporadic cases. Probands displayed CMT1 (267),
CMT2 (375), intermediate (85), or unclassified peripheral
neuropathy (183). All exons, exon–intron boundaries, and
59UTR of SGPL1 were analyzed using custom-designed
MASTRTM assay (multiplicom.com/), followed by Sanger
sequencing validation.
Dosage analysis. Multiplex amplicon quantification assay
(multiplicom.com) included 15 amplicons encompassing
SGPL1 exons and 5 control amplicons. A dosage quotient
(DQ) was calculated by comparing normalized peak areas
between patients and controls; DQ ,0.5 indicated a deletion.
Lymphoblast cultures. Epstein-Barr virus–transformed lym-
phoblast cultures were maintained as described.10 To inhibit
nonsense-mediated mRNA decay (NMD), lymphoblasts were
incubated with 150 mg/mL cycloheximide (CHX, Sigma-
Aldrich, St. Louis, MO) or vehicle (DMSO, Sigma-Aldrich) for
4 hours, followed by RNA isolation and RT-PCR analysis. To
inhibit proteasome function, cells were treated with 40 mM
MG-132 (Calbiochem, San Diego) or vehicle (DMSO).
RNA isolation and RT-PCR. Total RNA of lymphoblasts was
extracted using RNeasy Mini Kit (Qiagen, Germantown, MD)
and treated with TURBO DNase (Applied Biosystems, Foster
City, CA). SGPL1 cDNA was synthesized using SuperScript III
First-Strand Synthesis System (Invitrogen, Carlsbad, CA).
Primers are listed in table e-1 at Neurology.org.
Immunoblotting. Protein extracts from lymphoblasts or
mouse tissues were isolated as described.10 Membranes were
immunoblotted with anti–sphingosine 1-phosphate lyase
(SPL) (1:200, R&D Systems, Minneapolis, MN; and
Atlas Antibodies, Stockholm, Sweden) or anti‐b‐actin
(1:20,000, Sigma‐Aldrich) antibodies. Results were
visualized by chemiluminescence detection (GE Healthcare,
Waukesha, WI).
Protein structure modeling. Chimera11 was used to visualize
SPL (pdb: 4Q6R)12 and to substitute the isoleucine184 for a thre-
onine with the swapaa command. The conformation of the thre-
onine side chain was modeled with the highest probability (96%)
based on an internal rotamer library, the lowest clash score, and
the largest amount of H-bonding interactions with the surround-
ing amino acids.
Lipid analysis. For lipid analysis, refer to e-Methods 1–4.
Drosophila stocks and analysis. For Drosophila stocks and
analysis, refer to e-Methods 1–4 and table e-2.
RESULTS Clinical findings. We present clinical data
of 2 affected siblings from a family of Serbian ethnicity
(figure 1A). The proband (II-1) developed walking
difficulties within several weeks at age 12 years, 1
month after intense stress and a febrile episode
(table 1). Initial neurologic examination revealed weak-
ness of distal lower limb (LL) muscles, more pro-
nounced in extensor muscle groups, absent Achilles
tendon reflexes, mildly diminished vibration sense at
the level of ankles, and mild scoliosis. The rest of the
examination was unremarkable. Within the following
months, wasting of distal LL muscles became promi-
nent, while their weakness plateaued (MRC 0–3). Ini-
tial NCS revealed undetectable compound muscle
action potentials and sensory nerve action potentials
for LL nerves and normal parameters for upper limb
(UL) nerves (table 2). EMG showed spontaneous
activity for distal LL muscles and a neuropathic pattern
for all examined distal LL and UL muscles. At ages 18
years and 21 years, the patient experienced 2 episodes
of muscle weakness in the distribution of the left ulnar
nerve, without any provocative events. Full recovery
occurred within 1 year after the first episode and only
partial improvement after the second. NCS supported
the diagnosis of axonal polyneuropathy (table 2) and
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the 2 episodes of left ulnar mononeuropathy were cor-
roborated by electrophysiologic findings (data not
shown). In the next 11 years, there were no changes
in his symptoms and signs. At the last clinical exami-
nation (age 32 years), he had mild motor deficit of the
left hand, in the distribution of the ulnar nerve, bilat-
eral severe motor impairment of the legs, and mildly
decreased vibration sense (figure 1B).
The younger sister (II-2) developed acute tran-
sient pain in the left foot without any provocative
events at age 11 years, followed by a weakness of left
foot plantar flexors, bilaterally decreased Achilles
tendon reflexes, and no sensory deficit (table 1).
NCS performed 2 months later showed normal elec-
trophysiology for the median nerve and abnormal
parameters for sural, peroneal, and tibial nerves,
more pronounced on the left side (table 2). NCS
findings were compatible with an axonal neuropa-
thy. Over the next 5 months, the disease progressed
and the most notable deficit was in the domain of
the left tibial nerve (weakness of foot plantar flexion
[PF] and toe flexion). Distal LL muscles showed
moderate weakness of the left toe extensor and very
mild weakness of the same muscle group on the
right. Improvement was noticed for left foot PF
within a few months. Two episodes of muscle weak-
ness followed, first at age 12 years in the distribution
of the left peroneal nerve and second at age 13 years
in the distribution of the right tibial nerve. Improve-
ment of right foot PF was detected in the follow-up
period. No further progression appeared over the
last 15 years. At the last clinical examination (age
28 years), she had asymmetrical distal LL motor
deficit and no sensory impairment (figure 1B).
Her functional status was very good.
Sural nerve biopsy of II-2 was performed 2
months after disease onset (data not shown). On
the teased preparation, about 20% of nerve fibers
showed active axonal disintegration. There were no
detectable regenerating axons or endoneurial fibrosis.
Additional evaluations of both patients included
blood tests with complete biochemical and immuno-
logic analysis, CSF analysis, physical examination,
and cognitive testing. All tests and examinations were
within normal limits. Involvement of CNS, or any
other systems and organs, was not noted.
Identification of SGPL1 as AR-CMT2 candidate gene.
WES was performed on patients II-1 and II-2. All
known CMT genes were initially analyzed, and
sequence gaps therein were covered by Sanger
sequencing; however, no causal variants were found.
WES-based homozygosity mapping revealed a low
number (6) and small size (maximum 6 Mb) of
shared autozygous regions, suggesting a compound
heterozygous recessive trait. WES data were
nevertheless filtered for both homozygous and
compound heterozygous shared variants, based on
novelty, effect on protein, population frequency, and
cosegregation (table e-3). No homozygous variants
fulfilled these criteria, while 2 heterozygous sequence
variations, c.551T.C (p.Ile184Thr) and c.1082C.G
(p.Ser361*), were identified in SGPL1 encoding SPL
(figure 2A). Both mutations were in trans, cosegregated
Figure 1 Pedigree and clinical features of the studied autosomal recessive Charcot-Marie-Tooth 2 family
(A) Family tree. Square symbols represent males and circles females. Black symbols indicate affected individuals. (B) Serial images of the patients. Patient II-
1 at age 32 presents with unilateral mild hypotrophy and weakness of the muscles in the first interosseal space, bilateral atrophy, and severe weakness
(Medical Research Council scale 0–2) of all distal leg muscles. Patient II-2 at age 28 has normal appearance of the distal muscles of the hands, unilateral
severe weakness of hallux extensor, and normal standing on tiptoe.
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with the phenotype, and were absent in 190 Serbian and
470 non-Serbian controls. Subsequently, 910 AR-CMT
and sporadic cases of various ethnicity were screened for
mutations in SGPL1. In 8 probands, single rare
heterozygous variants were identified (table e-4);
however, no in/dels were found on the second allele
using a gene dosage assay. No homozygous single
exon in/dels were found either. Thus, SGPL1
mutations are a very rare cause of AR-CMT.
SGPL1 mutational effects. The c.1082C.G nonsense
mutation is located in exon 12 (out of 15) of SGPL1
Table 1 Clinical findings
Patient II-1 (M) Patient II-2 (F)
Onset
Age at onset, y 12 11
Symptoms Acute/subacute onset,
symmetrical weakness of distal
LL muscles
Acute/subacute onset, unilateral pain and
weakness of left foot PF
Pattern of muscle weakness
UL proximal No No
UL distal No No
LL proximal No No
LL distal Severe, DF . PF (0/3) PF of left foot (3)
Muscle wasting No No
Reflexes Absent Achilles tendon reflexes
bilaterally
Decreased Achilles tendon reflexes bilaterally
Sensory involvement Vibration sensation decreased
in LL
No
CMTNS 8 5
Episodic deficit
Age, y 18 21 12 13
Description Unprovoked ulnar
mononeuropathy,
left side, full
recovery
Unprovoked ulnar
mononeuropathy,
left side, residual
deficit
Unprovoked
peroneal
mononeuropathy,
left side, residual
deficit
Unprovoked tibial
mononeuropathy,
right side,
recovery foot PF,
but not toe flexion
Stationary period from last episode
Duration, y 11 15
Last clinical follow-up
Age, y 32 28
Pattern of muscle weakness
UL proximal No No
UL distal Abduction/adduction of fingers, adduction of
thumb, left side (4)
No
LL proximal No No
LL distal DF foot (0), PF foot (2), toe extension (0), toe
flexion (0)
DF foot R/L (5/3), PF foot R/L (5/5), toe
extension R/L (4/3), toe flexion R/L (3/4), hallux
extension R/L (5/0)
Muscle wasting UL distal First dorsal interosseous space, hypothenar
eminence (left hand)
No
Muscle wasting LL distal Yes Foot muscles
Sensory involvement Vibration sensation decreased in LL No
CMTNS 15 5
Contractures/foot/skeletal deformities No/no/scoliosis No/pes planus-valgus/no
CNS involvement No No No No
Other systems/organs Not affected Not affected Not affected Not affected
Abbreviations: CMTNS 5 Charcot-Marie-Tooth disease neuropathy score; DF 5 dorsal flexion; LL 5 lower limbs; PF 5 plantar flexion; UL 5 upper limbs.
Muscle weakness was evaluated using the Medical Research Council grading scale.
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and therefore might trigger NMD.13 Sanger sequencing
of SGPL1 cDNA derived from lymphoblasts did not
reveal the c.1082 G allele in the father or the patients,
resulting in an ostensible homozygosity for the c.551C
mutation in the affected individuals (figure 2A).
Inhibition of NMD with CHX restored the cDNA
heterozygosity for both mutations, suggesting that the
c.1082 G allele was post-transcriptionally degraded. In
the patients, SPL function would then be secured by the
remaining c.551C-allele encoding p.Ile184Thr protein.
In silico structural analysis showed that isoleucine184
lies within a stretch of 8 hydrophobic residues. The p.
Ile184Thr mutation substitutes an aliphatic by a polar
residue, disrupting the hydrophobic core and causing
protein instability (figure 2B). Accordingly, the protein
was nearly undetectable in lymphoblast lysates from the
patients compared to controls upon immunoblotting
analysis with 2 different anti-SPL antibodies (figure
2C). MG-132 treatment of cells from patient II-2
induced SPL accumulation, indicating that the
mutant protein is translated but unstable and subject
to degradation (at least in part) via the proteasomal
system (figure 2D). This suggests that the SGPL1
mutations affect transcription and protein expression,
leading to a depletion of SPL function. SPL catalyzes
the degradation of S1P in the last step of sphingolipid
catabolism. Therefore, we analyzed the S1P and total
sphingoid base levels in plasma of patients, parents, and
unrelated controls. S1P levels appeared to be generally
lower in the parents compared to the control average
but were significantly elevated in patients (figure 2E).
Also, the ratio of total sphingosine/sphinganine (SO/
SA) was significantly increased in patient plasma
(figure 2F).
SPL downregulation in Drosophila neurons. SPL is an
essential and evolutionary conserved enzyme ex-
pressed in multiple tissues14 including sciatic nerve
(figure e-1). In Drosophila melanogaster, SPL has no
paralogues and one orthologue (Sply, CG8946), shar-
ing 49% identity and 68% similarity with the human
protein.15 Sply-deficient flies exhibit compromised
muscle development, decreased fecundity, and semi-
lethality.15 Because our patients present with neuro-
logic symptoms, we downregulated Sply exclusively in
the nervous system, using RNAiSply expressed by the
pan-neuronal driver nsyb-Gal4, and assessed NMJ
morphology in third instar larvae. This in vivo
paradigm has been widely used to study the effect of
genes causing neurodegeneration.16,17 For control
purposes, we RNAi-downregulated Myc, an essential
gene for synapse development,16 and Smn, a gene
associated with spinal muscular atrophy (SMA).17 To
account for random RNAi effects, antisense oligos
against genes not transcribed in neurons (Cup and S-
Lap5) were expressed.
In control flies, we observed mature NMJs charac-
terized by beads-on-a-string-like structures formed at
the axon terminus (figures 3A and e-2). In contrast,
neuronal downregulation of Sply using RNAis target-
ing different transcript regions reduced NMJ arboriza-
tion and decreased the number of synaptic boutons
(figure 3, B–C). As expected, NMJ effects were
observed when downregulating both neuronally rele-
vant control genes.16,17 No differences in NMJ length
were found. These findings demonstrate a role for Sply
in maintaining the morphology of axonal terminals.
To determine whether Sply downregulation might
cause axonal neurodegeneration, similarly to Smn, we
Table 2 Electrophysiologic findings
Patient II-1 Patient II-2
Median
nerve
Ulnar
nerve
Peroneal
nerve
Tibial
nerve
Median
nerve
Ulnar
nerve
Peroneal
nerve
Tibial
nerve
Motor conduction studies
Amp CMAP/MCV
NCS at onset R: 3.2/52.6 R: 5.3/49.5 NR NR R: 8.0/56.5 ND R: Rec; L: NR R: Rec; L: NR
NCS at last examination R: 4.7/41.8; L: 1.6/38.3 R: 8.5/56.1; L: 2.2/47.6 NR NR R: 7.1/49.6 ND R: 1.0/30.3; L: ND R: 0.1/NR; L: 0.1/NR
Patient II-1 Patient II-2
Median nerve Ulnar nerve Sural nerve
Median
nerve Ulnar nerve Sural nerve
Sensory conduction studies
Amp SNAP/SCV
NCS at onset R: 52.6/50.0 ND NR R: 64.9/60.0 ND R: 4.6/40.5
NCS at last examination NR R: 25.0/48.9; L: NR NR R: 33.0/65.1 R: 27.0/53.7 NR
Abbreviations: Amp 5 amplitude (measured in mV for the motor and in mV for the sensory nerves); CMAP 5 compound muscle action potential; MCV 5
motor conduction velocity (measured in m/s); NCS 5 nerve conduction study; ND 5 not done; NR 5 not recordable; Rec 5 recordable; SCV 5 sensory nerve
conduction velocity (measured in m/s); SNAP 5 sensory nerve action potential.
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expressed RNAiSply in the chemosensory neurons
innervating the wing margin bristles (dpr-Gal4 driver)
visualized by the red fluorescent protein mCherry
(UAS-mCD8chRFP, figure e-3). While at day 1 post-
eclosion the wing neurons looked comparable in flies
with different genotypes, from day 20 onward pro-
nounced fragmentation of the mCherry signal
was noted in flies expressing RNAiSply or RNAiSmn
(figure 3, E–F). These results demonstrate that neu-
ronal depletion of Sply induces progressive axonal
degeneration in Drosophila.
DISCUSSION Currently known genes explain only
;40% of AR-CMT cases, suggesting many
unidentified genetic causes.18 Here, we provide genetic
and functional evidence that SGPL1 is a candidate
Figure 2 Sphingosine 1-phosphate (S1P) lyase (SPL): Transcript, protein, and metabolite analysis
(A) Electropherograms around the 2 mutations in SGPL1 (c.551T.C and c.1082C.G) upon analyzing genomic DNA (gDNA) or complementary DNA (cDNA)
isolated from peripheral mononuclear blood cells, before and after cycloheximide (CHX) treatment. (B) Crystal structure of the dimeric human sphingosine
1-phosphate lyase, adapted from pdb 4Q6R. The 2 subunits (A, B) of the dimeric protein are displayed in tan and blue ribbons, respectively. Top right: zoom in
view shows the Ile184 residue that is surrounded by 7 other hydrophobic residues (i.e., Ala163, Phe167, Leu181, Ala402, Trp405 from subunit A; Leu130,
Tyr133 from subunit B) to constitute a hydrophobic core. Bottom right: the p.Ile184Thr mutation substitutes the long aliphatic side chain of isoleucine with
a small and polar hydroxyl group of threonine in the middle of the hydrophobic core. (C) Immunoblotting analysis of SPL in 20 mg of protein lysates of
lymphoblast cultures from all family members and 7 healthy control individuals. b-actin is used as loading control. Chemiluminescence exposure time of 60
seconds. (D) Immunoblotting analysis of SPL in 30 mg of protein lysates of lymphoblasts of patient II-2 incubated with vehicle alone (DMSO), with the MG-
132 proteasome inhibitor, or nontreated (NT). SPL accumulates in a time-dependent manner in cells from the patient, compared to the control. b-actin
demonstrates equal loading. Chemiluminescence exposure time of 600 seconds. (E) S1P levels in plasma of patents, patients, and unrelated controls (n 5
24). (F) Total sphingosine/sphinganine (SO/SA) ratio after hydrolysis in plasma of patients, parents, and unrelated controls (n5 3). (E, F) Error bars represent
the SD. ***p , 0.001; ns 5 nonsignificant (one-way analysis of variance with Bonferroni multiple comparison test against the control group).
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AR-CMT gene. The associated phenotype is distinct
from other AR-CMT2 subtypes and is characterized
by acute/subacute onset, unilateral motor deficit in
one patient, and episodes of mononeuropathy with
a tendency for improvement in both patients.
The deterioration pattern seen in both patients is
atypical for axonal CMT. Rather, it is observed in
acquired neuropathies,19 hereditary neuropathies with
liability to pressure palsies (HNPP), or hereditary
neuralgic amyotrophy (HNA).20 As opposed to the
Figure 3 Analysis of neuron-specific Sply deficiency in Drosophila
(A) Immunolabeling of presynaptic (anti-HRP antibody, green) and postsynaptic (anti-DLG antibody, magenta) compartments of the neuromuscular junctions
(NMJs) in third instar larvae, pan-neuronally (nsyb-Gal4) expressing RNAi constructs against Sply (Sply knockdown; RNAiSply[1],RNAiSply[2]), neuronally relevant
genes (RNAiSmn, RNAiMyc), genes not expressed in neurons (RNAi controls; RNAiCup, RNAiS-Lap5[1], RNAiS-Lap[2]), or the driver alone (control genetic background;
nsyb-Gal4/1). Scale bar, 20 mm. (B–D) Quantitative analysis of the NMJ phenotypes. Maximum intensity projections of Z-stacks comprising the full NMJ
were used. The number of boutons per NMJ (B) was counted using the Cell Counter plugin. ImageJ was used to count the number of individual branch
segments (C) and calculate the total NMJ length (D). Error bars represent the SD of at least 13 NMJs per genotype. *p , 0.05; ***p , 0.001; ns 5
nonsignificant (one-way analysis of variance with Bonferroni multiple comparison test against the control genetic background). (E) Nerve tract along the wing
L1 vein visualized bymCherry, where RNAi constructs are expressed using the dpr-Gal4 driver. Representative images of wings are shown for day 1 and day
201 old flies expressing the driver alone (Dpr-Gal4/1), neuronally relevant gene (RNAiSmn), or Sply (RNAiSply[1]). Scale bar, 20 mm. (F) Quantification of the
number of wings showing axonal fragmentation per genotype (n 5 30–60/genotype).
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AR-CMT in our family, HNPP and HNA are dom-
inantly inherited. HNPP presents as recurrent pain-
less focal neuropathy that, contrary to our patients, is
demyelinating in nature. Sural nerve biopsies of pa-
tients with HNPP show segmental demyelination
and remyelination, which are not found in the nerve
specimen of II-2. HNA is characterized by triggered
transient painful episodes of brachial or less fre-
quently lumbar plexus neuropathy with muscle weak-
ness and atrophy. Apart from axonal neuropathy in
the implicated nerve, electrophysiology is normal.
Contrastingly, our patients exhibit clear neurophysi-
ologic evidence of broader neuropathy than clinical
signs expressed. The biopsy findings also lack some
characteristic histopathologic features of CMT2;
however, this might be due to the unusual onset
and sampling too early in the disease course. Even
though the phenotype in our patients could resemble
one of inflammatory neuropathy,21 coexistence of
hereditary and inflammatory neuropathy was
excluded. Provocative factors were not reported in
any but the first episode in the proband. Overall,
the neurologic presentation of our patients extends
the currently recognized clinical spectrum of in-
herited peripheral neuropathies.
We identified compound heterozygous SPL mu-
tations in patients with AR-CMT. p.Ser361* trig-
gers NMD in patients’ cells. p.Ile184Thr changes
a nonpolar to polar amino acid, leading to protein
instability and subsequent degradation. While the
degree of degradation might differ between tissues,
this finding supports the hypothesis that the
observed CMT phenotype is due to SPL deficiency.
Notably, we detected trace amounts of SPL in
patient lymphoblasts compared to controls. This
result, together with the fact that Ile184 is located
outside of the catalytic pocket, suggests that the
mutant has some residual activity.
SPL catalyzes the irreversible degradation of S1P
into phosphoethanolamine and hexadecenal in the
final step of sphingolipid catabolism.22,23 Phosphoe-
thanolamine can be used for phospholipid synthesis.
Alternatively, S1P may re-enter the sphingolipid
metabolism by dephosphorylation to sphingosine
and subsequent conversion to ceramide and complex
sphingolipids. S1P itself is a potent signaling mole-
cule involved in cell migration, proliferation, and apo-
ptosis.22 Thus, SPL acts at the crossroad of
sphingolipid and phospholipid metabolism, and plays
a pivotal role in fine-tuning the concentrations of its
bioactive substrate. In patient plasma, S1P levels were
significantly increased compared to parents or unre-
lated controls. In parallel, the patients showed a sig-
nificant increase in the total SO/SA ratio, indicating
that the relative proportion of individual sphingolipid
subspecies is altered.
Sgpl2/2mice display growth retardation and severe
congenital multisystemic abnormalities, leading to
premature death.24 Brain morphology is unremark-
able, but mice were not examined for neurologic
symptoms. Isolated cerebellar neurons, however, have
decreased viability and undergo neurodegeneration.25
They accumulate S1P, which is neurotoxic25,26 and
causes calpain activation, cell cycle re-entry, and ulti-
mately apoptosis.25 Thus, neuron-specific defects
likely exist in Sgpl2/2 mice, but are masked by the
severe impairment of other systems. Flies with sys-
temic Sply deficiency exhibit developmental lethality,
abnormal flight muscle development and integrity,
impaired locomotion, decreased fecundity, and
enhanced apoptosis.15
Using our experience in modeling CMT in
Drosophila,27,28 we aimed to disentangle the neuron-
specific from somatic effects of SPL deficiency.
Because of the dying-back neuropathy in our patients,
we investigated the Drosophila NMJ, a powerful sys-
tem for studying synaptic development, morphology,
and function.29 Moreover, this is a valid model for
genetic and molecular analysis of neuromuscular dis-
orders like CMT27,30–32 and SMA.17 Silencing Sply in
the fly nervous system induced characteristic NMJ
morphologic defects. Similar abnormalities were
observed when knocking downMyc or Smn, essential
genes for neuronal development or involved in neu-
romuscular pathologies, respectively.16,17 To better
distinguish developmental from neurodegeneration
effects, we applied a second in vivo paradigm, where
we downregulated Sply in the long chemosensory
neurons in the wings of adult flies. Remarkably, Sply
deficiency caused age-dependent destruction of axo-
nal integrity, thereby demonstrating its causal
involvement in axonal degeneration. In this way,
our functional genomics approach provided indepen-
dent evidence for the essential function of SPL in
neurons in vivo. Furthermore, we demonstrate that
the fruit fly is a functional tool to validate candidate
genes involved in neurodegeneration.
Neurons depend on sphingolipids for axon guid-
ance, neurotrophin signaling, and synaptic transmis-
sion.33 Within the CMT category, mutations in
SPTLC1 and SPTLC2 encoding subunits of serine
palmitoyltransferase cause hereditary sensory and
autonomic neuropathy type I.34,35 Defects in
sphingolipid-metabolizing enzymes lead to AR neu-
rometabolic disorders with highly variable onset,
development, and symptoms.36 This variability de-
pends mainly on the cell-type specific pattern of
sphingolipid expression or uptake, and the residual
activity of the defective enzyme. A complete enzyme
deficiency leads to early onset and severe course, pre-
senting as a neurologic and somatic fatal disorder.
Patients whose cells retain traces of residual activity
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will have an attenuated course with less somatic signs,
or can be clinically undiagnosed and detected as
accidental biochemical finding.36,37 Introducing
next-generation sequencing into the clinical workup,
together with deep phenotyping, will allow identifi-
cation of such rare neurometabolic patients.38 Our
study illustrates this threshold concept by demon-
strating that partial loss of SPL function leads to
a noncongenital disorder exclusively affecting periph-
eral nerves. Molecular studies of additional cases of
SPL deficiency will help delineate its full clinical
spectrum.
We demonstrate that biallelic mutations in SGPL1
may lead to a distinct CMT phenotype and confirm
the importance of the sphingolipid metabolism for
neuronal function. Our findings have implications
for clinical and molecular diagnosis and potential
treatment strategy in patients with inherited periph-
eral neuropathies.
AUTHOR CONTRIBUTIONS
Derek Atkinson, Jelena Nikodinovic Glumac: study concept and design,
acquisition of data, analysis and interpretation of data, drafting of the
manuscript for intellectual content. Biljana Ermanoska, Bob Asselbergh,
Alejandro Estrada-Cuzcano, Kristien Peeters, David Blocquel, Xiang-Lei
Yang, Regula Steiner, Thorsten Hornemann: acquisition of data, analysis
and interpretation of data, critical revision of manuscript for intellectual
content. Els De Vriendt, Tinne Ooms: acquisition of data, analysis and
interpretation of data. Albena Jordanova, Vedrana Milic Rasic: study con-
cept and design, acquisition of data, analysis and interpretation of data,
drafting of the manuscript for intellectual content, study supervision.
ACKNOWLEDGMENT
The authors thank the family members for their participation, the Ge-
nomics Service Facility of the VIB Department of Molecular Genetics
(VIB-DMG, Belgium) for sequencing and cell maintenance support,
the VIB-DMG Bioinformatics Unit for next-generation sequencing data
analysis, and Dr. Maria-Luise Erfurth and Prof. Ivo Kremensky for
discussions.
STUDY FUNDING
This study was funded in part by the University of Antwerp (TOP BOF
29069 to A.J.), the Fund for Scientific Research-Flanders (FWO,
G.0543.13 and G0D7713N, to A.J.), the Belgian Association against
Neuromuscular Disorders (ABMM to A.J.), and the NIH (NS 085092
to X.-L.Y. and A.J.). D.A. and A.E-C. are supported by fellowships from
the Fund for Scientific Research-Flanders.
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received June 13, 2016. Accepted in final form November 16, 2016.
REFERENCES
1. Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth
disease. J Peripher Nervous Syst 2011;16:1–14.
2. Ouvrier R. What can we learn from the history of
Charcot-Marie-Tooth disease? Dev Med Child Neurol
2010;52:405–406.
3. Davis CJ, Bradley WG, Madrid R. The peroneal muscu-
lar atrophy syndrome: clinical, genetic, electrophysiolog-
ical and nerve biopsy studies: I: clinical, genetic and
electrophysiological findings and classification. J Genet
Hum 1978;26:311–349.
4. Dubourg O, Azzedine H, Verny C, et al. Autosomal-recessive
forms of demyelinating Charcot-Marie-Tooth disease.
Neuromolecular Med 2006;8:75–86.
5. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical
implications of genetic advances in Charcot-Marie-Tooth
disease. Nat Rev Neurol 2013;9:562–571.
6. Heckman JD. Electrodiagnosis in diseases of nerve and
muscle. Orthopedics 1984;7:601–604.
7. Drulovic J, Dozic S, Levic Z, et al. Unusual association of
multiple sclerosis and tomaculous neuropathy. J Neurol
Sci 1998;157:217–222.
8. Reumers J, De Rijk P, Zhao H, et al. Optimized filtering
reduces the error rate in detecting genomic variants by
short-read sequencing. Nat Biotechnol 2011;30:61–68.
9. Kancheva D, Atkinson D, De Rijk P, et al. Novel muta-
tions in genes causing hereditary spastic paraplegia and
Charcot-Marie-Tooth neuropathy identified by an
optimized protocol for homozygosity mapping based
on whole-exome sequencing. Genet Med 2015;18:
600–607.
10. Zimon M, Baets J, Almeida-Souza L, et al. Loss-of-function
mutations in HINT1 cause axonal neuropathy with
neuromyotonia. Nat Genet 2012;44:1080–1083.
11. Pettersen EF, Goddard TD, Huang CC, et al. UCSF
Chimera: a visualization system for exploratory research
and analysis. J Comput Chem 2004;25:1605–1612.
12. Weiler S, Braendlin N, Beerli C, et al. Orally active
7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-
1-yl]nicotinonitriles as active-site inhibitors of sphingosine
1-phosphate lyase for the treatment of multiple sclerosis.
J Med Chem 2014;57:5074–5084.
13. Hentze MW, Kulozik AE. A perfect message: RNA sur-
veillance and nonsense-mediated decay. Cell 1999;96:
307–310.
14. Bektas M, Allende ML, Lee BG, et al. Sphingosine
1-phosphate lyase deficiency disrupts lipid homeostasis in
liver. J Biol Chem 2010;285:10880–10889.
15. Herr DR, Fyrst H, Phan V, et al. Sply regulation of sphin-
golipid signaling molecules is essential for Drosophila
development. Development 2003;130:2443–2453.
16. Oortveld MA, Keerthikumar S, Oti M, et al. Human
intellectual disability genes form conserved functional
modules in Drosophila. PLoS Genet 2013;9:e1003911.
17. Chang HC, Dimlich DN, Yokokura T, et al. Modeling
spinal muscular atrophy in Drosophila. PLoS One 2008;3:
e3209.
18. Zimon M, Battaloglu E, Parman Y, et al. Unraveling the
genetic landscape of autosomal recessive Charcot-Marie-
Tooth neuropathies using a homozygosity mapping
approach. Neurogenetics 2015;16:33–42.
19. Ryan MM, Tilton A, De Girolami U, Darras BT, Jones
HR Jr. Paediatric mononeuritis multiplex: a report of
three cases and review of the literature. Neuromuscul
Disord 2003;13:751–756.
20. Stogbauer F, Young P, Kuhlenbaumer G, De Jonghe P,
Timmerman V. Hereditary recurrent focal neuropathies:
clinical and molecular features. Neurology 2000;54:
546–551.
21. Rajabally YA, Adams D, Latour P, Attarian S. Hereditary
and inflammatory neuropathies: a review of reported asso-
ciations, mimics and misdiagnoses. J Neurol Neurosurg
Psychiatry 2016;87:1051–1060.
Neurology 88 February 7, 2017 541
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
22. van Echten-Deckert G, Hagen-Euteneuer N, Karaca I,
Walter J. Sphingosine-1-phosphate: boon and bane for
the brain. Cell Physiol Biochem 2014;34:148–157.
23. Bandhuvula P, Saba JD. Sphingosine-1-phosphate lyase in
immunity and cancer: silencing the siren. Trends Mol
Med 2007;13:210–217.
24. Schmahl J, Raymond CS, Soriano P. PDGF signaling
specificity is mediated through multiple immediate early
genes. Nat Genet 2007;39:52–60.
25. Hagen N, Hans M, Hartmann D, Swandulla D,
van Echten-Deckert G. Sphingosine-1-phosphate links
glycosphingolipid metabolism to neurodegeneration via
a calpain-mediated mechanism. Cell Death Differ 2011;
18:1356–1365.
26. Hagen-Euteneuer N, Lutjohann D, Park H,
Merrill AH Jr, van Echten-Deckert G. Sphingosine
1-phosphate (S1P) lyase deficiency increases sphingoli-
pid formation via recycling at the expense of de novo
biosynthesis in neurons. J Biol Chem 2012;287:
9128–9136.
27. Ermanoska B, Motley WW, Leitao-Goncalves R, et al.
CMT-associated mutations in glycyl- and tyrosyl-tRNA
synthetases exhibit similar pattern of toxicity and share
common genetic modifiers in Drosophila. Neurobiol Dis
2014;68:180–189.
28. Storkebaum E, Leitao-Goncalves R, Godenschwege T,
et al. Dominant mutations in the tyrosyl-tRNA synthetase
gene recapitulate in Drosophila features of human Charcot-
Marie-Tooth neuropathy. Proc Natl Acad Sci USA 2009;
106:11782–11787.
29. Miller DL, Ballard SL, Ganetzky B. Analysis of synaptic
growth and function in Drosophila with an extended larval
stage. J Neurosci 2012;32:13776–13786.
30. Niehues S, Bussmann J, Steffes G, et al. Impaired protein
translation in Drosophila models for Charcot-Marie-Tooth
neuropathy caused by mutant tRNA synthetases. Nat
Commun 2015;6:7520.
31. Lopez Del Amo V, Seco-Cervera M, Garcia-Gimenez JL,
Whitworth AJ, Pallardo FV, Galindo MI. Mitochondrial
defects and neuromuscular degeneration caused by altered
expression of Drosophila Gdap1: implications for the
Charcot-Marie-Tooth neuropathy. Hum Mol Genet
2015;24:21–36.
32. Janssens K, Goethals S, Atkinson D, et al. Human Rab7
mutation mimics features of Charcot-Marie-Tooth neu-
ropathy type 2B in Drosophila. Neurobiol Dis 2014;65:
211–219.
33. Tsui-Pierchala BA, Encinas M, Milbrandt J, Johnson EM,
Jr. Lipid rafts in neuronal signaling and function. Trends
Neurosci 2002;25:412–417.
34. Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-GrumbachM,
Nicholson GA. Mutations in SPTLC1, encoding serine
palmitoyltransferase, long chain base subunit-1, cause
hereditary sensory neuropathy type I. Nat Genet 2001;
27:309–312.
35. Rotthier A, Auer-Grumbach M, Janssens K, et al. Muta-
tions in the SPTLC2 subunit of serine palmitoyltransferase
cause hereditary sensory and autonomic neuropathy type I.
Am J Hum Genet 2010;87:513–522.
36. Kolter T, Sandhoff K. Sphingolipid metabolism diseases.
Biochim Biophys Acta 2006;1758:2057–2079.
37. Rapola J. Lysosomal storage diseases in adults. Pathol Res
Pract 1994;190:759–766.
38. Tarailo-Graovac M, Shyr C, Ross CJ, et al. Exome
sequencing and the management of neurometabolic disor-
ders. N Engl J Med 2016;374:2246–2255.
Visit the Neurology® Resident & Fellow Website
Click on Residents & Fellows tab at Neurology.org.
Now offering:
• Neurology® Resident & Fellow Editorial team information
• “Search by subcategory” option
• E-pearl of the Week
• RSS Feeds
• Direct links to Continuum®, Career Planning, and AAN Resident & Fellow pages
• Recently published Resident & Fellow articles
• Podcast descriptions
Find Neurology® Residents & Fellows Section on Facebook: http://tinyurl.com/o8ahsys
Follow Neurology® on Twitter: http://twitter.com/GreenJournal
542 Neurology 88 February 7, 2017
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/WNL.0000000000003595
2017;88;533-542 Published Online before print January 11, 2017Neurology 
Derek Atkinson, Jelena Nikodinovic Glumac, Bob Asselbergh, et al. 
Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy
This information is current as of January 11, 2017
Services
Updated Information &
 http://n.neurology.org/content/88/6/533.full.html
including high resolution figures, can be found at:
Supplementary Material
 595.DC1
http://n.neurology.org/content/suppl/2017/01/11/WNL.0000000000003
Supplementary material can be found at: 
References
 http://n.neurology.org/content/88/6/533.full.html##ref-list-1
This article cites 38 articles, 7 of which you can access for free at: 
Subspecialty Collections
 http://n.neurology.org//cgi/collection/peripheral_neuropathy
Peripheral neuropathy
 http://n.neurology.org//cgi/collection/all_genetics
All Genetics
 http://n.neurology.org//cgi/collection/all_clinical_neurology
All Clinical Neurology
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://n.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://n.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
1951, it is now a weekly with 48 issues per year. Copyright © 2017 American Academy of Neurology. All 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
